<DOC>
	<DOCNO>NCT00113828</DOCNO>
	<brief_summary>The purpose trial determine patient hematologic disease HLA 6/6 match relate donor eligible standard myeloablative stem cell transplant less severe graft versus host disease ( GVHD ) , transplant related mortality , less graft failure treat non-myeloablative T-cell deplete stem cell transplant .</brief_summary>
	<brief_title>Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation Hematologic Malignancies</brief_title>
	<detailed_description>Our prior experience lab clinical trial non-myeloablative HLA-matched mismatch transplant strategy remarkable low transplant relate mortality rate , still formidable risk GVHD graft rejection . In trial , incorporate combination ex-vivo T-cell depletion strategy prevent GVHD vigorous vivo depletion host ( lesser extent donor ) T-cells prevent graft rejection . Patients receive non-myeloablative conditioning cyclophosphamide , thymoglobulin , fludarabine , thymic irradiation , follow T-cell deplete PBSC infusion . Cyclosporine give GVHD prophylaxis , taper begin day 35 . Data mouse model previous clinical trial demonstrate approach induce mixed chimerism without GVHD , potential conversion mixed chimerism full donor hematopoiesis follow donor leukocyte infusion .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Disease statue : NHL , HD , MM chemorefractory relapse ; CLL Rai Stage III/IV , lymphocyte double time 6 month , stage I/II resistant &gt; 2 chemotherapy regimen ; AML ALL 1st subsequent remission poor prognostic feature ; CML accelerate blast phae ; MDS lifethreatening cytopenia ; patient previous autologous allogeneic bone marrow stem cell transplant ; hematologic disorder allogeneic stem cell transplantation appropriate risk conventional transplantation consider unacceptably high . Estimated diseasefree survival less one year ECOG performance status 0 , 1 , 2 HLAgenotypically phenotypically match ( A , B , DR locus ) relate donor Patients life expectancy limit disease hematologic malignancy . Cardiac Disease : symptomatic congestive hearth failure , RVG , ejection fraction &lt; 45 % , active angina pectoris , uncontrolled hypertension . Pulmonary Disease : severe chronic obstructive lung disease , symptomatic restrictive lung disease , DLCO &lt; 50 % . Renal Disease : serum creatinine &gt; 2.0 mg/dl creatinine clearance &lt; 50 ml/min . Hepatic Disease : serum bilirubin &gt; 2.0 mg/dl alkaline phosphatase , SGOT SGPT &gt; 3 time normal . Neurologic Disease : symptomatic leukoencephalopathy , active CNS malignancy neuropsychiatric abnormality believe preclude transplantation HIV HTLV I antibody Hepatitis B surface antigen positivity Uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Non-Myeloablative</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>T-cell Depletion</keyword>
	<keyword>HLA-Matched</keyword>
</DOC>